How Long Should You Take Allergy Shots? Guidelines and Decision Criteria

The minimum recommended duration for post-treatment benefit from allergy shots is 3 years at maintenance dose, per AAAAI/ACAAI Practice Parameter (Cox et al., JACI 2011), EAACI guidelines (Roberts et al., Allergy 2018), and WHO position papers. This 3-year minimum applies to the maintenance phase — the time at full therapeutic dose — not the total treatment duration including build-up. Patients who stop at 2 years show significantly faster relapse rates than those completing 3+ years. EAACI guidelines explicitly state that 2-year courses produce insufficient post-treatment durability. The 3-year minimum is not arbitrary — it reflects the time required for regulatory T-cell tolerance to become stable enough to persist after stopping allergen exposure.

Stopping after 3 years of maintenance is clinically acceptable for many patients, provided the stopping criteria are met: near-complete symptom resolution through 2 consecutive relevant allergen seasons, good medication reduction, and adequate allergen-specific IgG4 response (if monitored). The AAAAI/ACAAI Practice Parameter describes 3 years as the first stopping window, with the decision individualized based on patient response, allergen type, disease severity, and patient preference. Patients who have experienced clear benefit over 3 years have a reasonable probability of 3-7 years of post-treatment benefit. Those with severe initial disease, prior relapse, or ongoing significant symptoms should continue to 4-5 years or discuss extension with their allergist.

Available evidence suggests 5 years of maintenance provides marginally better post-treatment durability than stopping at 3 years, though definitive head-to-head prospective data are lacking. A retrospective analysis (Naclerio et al., JACI 1997) suggested longer courses produced lower relapse rates. The intuitive biological rationale is strong: more years of allergen exposure means more deeply established regulatory T-cell tolerance and more stable IgG4-producing B-cell memory. However, the marginal benefit of years 4-5 over year 3 must be weighed individually against the ongoing cost and visit burden. Most guidelines describe the 3-5 year window as a range rather than a fixed endpoint precisely because the optimal stopping point varies by patient, allergen, and treatment response.

The primary stopping criterion per AAAAI/ACAAI guidelines is being symptom-free or near-symptom-free through 2 consecutive relevant allergen seasons while at maintenance dose. Secondary indicators include: substantial reduction in rescue medication use (ideally 50%+ from baseline), sustained improvement in quality-of-life scores, and at least 3 years of maintenance completed. Some allergists use declining skin prick test reactivity or improving IgG4/IgE ratios as supplementary biomarkers, though these are not universally standard (Peng and Arthur, Curr Allergy Asthma Rep 2020). The stopping conversation should begin at the 3-year maintenance mark if clinical response criteria are met — the decision is shared between patient and allergist, not a unilateral guideline mandate.

Extension beyond 5 years is recommended for several specific patient profiles per the AAAAI/ACAAI Practice Parameter (Cox 2011). Patients with severe initial allergic disease who had major quality-of-life impairment before treatment benefit from the additional durability of extended courses. Patients who previously completed a SCIT course and relapsed are typically recommended to extend to 5+ years on their second course to maximize durability. Patients with unstable or difficult-to-control asthma should continue as long as asthma control is benefiting from immunotherapy. Those with occupational allergen exposure — veterinarians with animal dander, laboratory workers with rodent allergens, outdoor workers with pollen — may benefit from indefinite continuation given the impossibility of allergen avoidance.

No — stopping allergy shots does not require a gradual taper or dose reduction. When the decision to discontinue is made, the maintenance dose is simply stopped without a tapering schedule (Cox 2011). This is one way allergy shots differ from corticosteroids or other medications that require tapering to avoid withdrawal effects. The discontinuation decision itself takes into account timing — most allergists prefer to stop after the end of the patient's primary allergen season rather than mid-season, to avoid leaving the patient's immune system in a partially trained state at the point of highest allergen exposure. There is no pharmacological reason for tapering — the decision is purely about clinical timing.

Continuing allergy shots indefinitely — beyond the recommended 3-5 year window — is generally safe but not evidence-based for most inhalant allergens. The AAAAI/ACAAI Practice Parameter notes that maintenance can be extended for specific patient populations (severe initial disease, occupational exposure, prior relapse), but routine continuation beyond 5 years without clear ongoing clinical indication is not recommended because post-5-year benefit increment is poorly documented and the ongoing cost and visit burden is not justified for most patients. Venom immunotherapy is the exception: indefinite continuation is specifically recommended for patients with mastocytosis, elevated baseline tryptase, severe initial systemic reactions, or systemic reactions during VIT treatment, based on clear data showing these patients have meaningfully higher relapse rates after stopping.